Africa's largest pharmaceutical manufacturer, Aspen Pharmacare Holdings Ltd., is setting its sights on securing regulatory approval in Canada for its generic version of the GLP-1 obesity treatment semaglutide by September. This strategic move could grant the South Africa-based company an early advantage in a crucial market following the expiration of Novo Nordisk A/S's patent for Ozempic.
Patent Expiration Opens Door for Generics
The core patent for semaglutide, initially filed by Novo Nordisk in March 2006, is now expiring in countries where extensions were not granted. In Canada, patent protection was the first to lapse due to missed maintenance fee payments, with data exclusivity that previously blocked generic competitors ending on January 4, 2026.
Chief Executive Stephen Saad stated in an interview that Aspen is targeting approval between May and September for its copycat version of semaglutide, the active ingredient in Ozempic. Based in Durban, South Africa, the company aims to be among the first to market in Canada, leveraging this approval as a reference for other nations that look to established regulators like Health Canada as benchmarks.
Strategic Market Entry and Global Implications
"You want to be within, say, six months of a first launch, to be part of market formation," Saad remarked on Tuesday, noting that Canada will likely be the initial market for its GLP-1 product. "Once we get Canada registration, it means we can use it as a reference for a lot of our Latin American countries, Middle Eastern countries."
Aspen's distribution of Eli Lilly & Co.'s blockbuster obesity drug Mounjaro in South Africa has served as a massive growth driver, according to Saad. However, the market dynamics for generics are expected to differ significantly, with an anticipated 12 to 15 manufacturers entering the space, leading to intensified price competition.
Competitive Pricing and Growth Prospects
Despite the competitive landscape, Saad projects that Aspen's sales volumes will be substantial, with GLP-1 drugs remaining a durable long-term growth driver for the company. Aspen plans to compete aggressively on price, asserting that even in Canada, it "absolutely can do that profitably." He anticipates rapid uptake in the country, given the high penetration of other generic medications.
Saad sees even greater potential in emerging markets, where patients often pay out of pocket, and a lower price point could unlock significant demand. "There are so many people that simply can't afford to pay the price of branded products," he emphasized, highlighting the accessibility benefits of generic alternatives.
Financial Performance and Future Plans
After investing heavily in GLP-1 manufacturing capabilities and reducing debt, Aspen is now reviewing its capital allocation strategy. While Saad does not foresee "any massive acquisitions ahead," he indicated that shareholder returns could be a topic of discussion in the near future.
Shares of Aspen closed 0.5 percent higher in Johannesburg, bringing their year-to-date gain to 16 percent. The company recently reported a 4.1 percent decline in first-half revenue to 21.1 billion rand (approximately US$1.3 billion), reflecting ongoing market adjustments.
This development marks a significant shift in the pharmaceutical landscape, as generic versions of popular GLP-1 drugs like Ozempic begin to enter key markets, potentially increasing affordability and access for patients worldwide.
